Protalix BioTherapeutics (PLX) Operating Leases (2019 - 2026)

Protalix BioTherapeutics has reported Operating Leases for 8 years, with the latest figure at $7.5 million in Q2 2026.

• On a quarterly basis, Operating Leases rose 94.51% year-over-year to $7.5 million in Q2 2026; TTM through Jun 2026 was $7.5 million, a 94.51% increase from a year earlier, with the FY2025 full-year figure at $6.9 million, up 72.31% from the prior year.
• Operating Leases was $7.5 million for Q2 2026 at Protalix BioTherapeutics, up from $7.0 million in the prior quarter.
• The five-year high for Operating Leases was $7.5 million in Q2 2026, with the low at $3.8 million in Q1 2025.
• Average Operating Leases over 5 years is $4.8 million, with a median of $4.2 million recorded in 2022.
• The sharpest annual moves came in 2025 and 2026: Operating Leases retreated 15.29% in 2025, then soared 94.51% in 2026.
• Over 5 years, Operating Leases stood at $4.2 million in 2022, then gained by 10.84% to $4.6 million in 2023, then declined by 12.88% to $4.0 million in 2024, then soared by 72.31% to $6.9 million in 2025, then climbed by 8.71% to $7.5 million in 2026.
• The last three Operating Leases figures came in at $7.5 million (Q2 2026), $7.0 million (Q1 2026), and $6.9 million (Q4 2025), per Business Quant data.